Strategies to enhance viral penetration of solid tumors

Human Gene Therapy

Volumn 22, Issue 9, 2011, Pages 1053-1060

  Smith, Elspeth ^a   Breznik, Jessica ^a   Lichty, Brian D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; MOUSE; NONHUMAN; PROGENY; SOLID TUMOR; TISSUE PRESSURE; TUMOR VASCULARIZATION; VIRUS ENTRY;

ANIMALS; EXTRACELLULAR MATRIX; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUSES;

EID: 80053000452     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2010.227     Document Type: Article

References (82)

1. Agarwal, D., Goodison, S., Nicholson, B., et al. (2003). Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation 71, 114-125. (Pubitemid 36359680)
2. Ahmed, A., Jevremovic, D., Suzuki, K., et al. (2003). Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Ther. 10, 1663-1671. (Pubitemid 37069494)
3. Balbin, M., Fueyo, A., Tester, A.M., et al. (2003). Loss of colla-genase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet. 35, 252-257. (Pubitemid 37363179)
4. Blackburn, J.S., Rhodes, C.H., Coon, C.I., and Brinckerhoff, C.E. (2007). RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res. 67, 10849-10858. (Pubitemid 350145914)
5. Bobo, R.H., Laske, D.W., Akbasak, A., et al. (1994). Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U.S.A. 91, 2076-2080. (Pubitemid 24092045)
6. Boucher, Y., and Jain, R.K. (1992). Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse. Cancer Res. 52, 5110-5114.
7. Breitbach, C.J., Paterson, J.M., Lemay, C.G., et al. (2007). Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15, 1686-1693. (Pubitemid 47289013)
8. Breitbach, C.J., De Silva, N.S., Falls, T.J., et al. (2011). Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19, 886-894.
9. Brekken, C., Bruland, O.S., and De Lange Davies, C. (2000). Interstitial fluid pressure in human osteosarcoma xenografts: Significance of implantation site and the response to intratumoral injection of hyaluronidase. Anticancer Res. 20, 3503-3512.
10. Brinkerhoff, C.J., Podsiadlo, P., Komiyama, T., et al. (2002). Protease inhibitors formed in situ from copper and tridentate chelates: A generalized approach towards metal-based pharmaceuticals. Chembiochem 3, 1141-1143. (Pubitemid 36008047)
11. Carty, N., Lee, D., Dickey, C., et al. (2011). Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. J. Neurosci. Methods 194, 144-153.
12. Chang, E., Chalikonda, S., Friedl, J., et al. (2005). Targeting vaccinia to solid tumors with local hyperthermia. Hum. Gene Ther. 16, 435-444. (Pubitemid 40647141)
13. Cheng, J., Sauthoff, H., Huang, Y., et al. (2007). Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol. Ther. 15, 1982-1990. (Pubitemid 350011738)
14. Choi, I.K., Lee, Y.S., Yoo, J.Y., et al. (2010). Effect of decorin on overcoming the extracellular matrix barrier for oncolytic vir-otherapy. Gene Ther. 17, 190-201.
15. Currier, M.A., Adams, L.C., Mahller, Y.Y., and Cripe, T.P. (2005). Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyo-sarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther. 12, 407-416. (Pubitemid 40411200)
16. Danielson, K.G., Baribault, H., Holmes, D.F., et al. (1997). Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell Biol. 136, 729-743. (Pubitemid 27083772)
17. Deryugina, E.I., and Quigley, J.P. (2006). Matrix metallo-proteinases and tumor metastasis. Cancer Metastasis Rev. 25, 9-34.
18. Doherty, F.C., Schaack, J.B., and Sladek, C.D. (2011). Comparison of the efficacy of four viral vectors for transducing hy-pothalamic magnocellular neurosecretory neurons in the rat supraoptic nucleus. J. Neurosci. Methods 197, 238-248.
19. Doronin, K., Toth, K., Kuppuswamy, M., et al. (2000). Tumor-specific, replication-competent adenovirus vectors over-expressing the adenovirus death protein. J. Virol. 74, 6147-6155. (Pubitemid 30412986)
20. Doronin, K., Toth, K., Kuppuswamy, M., et al. (2003). Over-expression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 305, 378-387. (Pubitemid 36259672)
21. Eikenes, L., Bruland, O.S., Brekken, C., and de Lange Davies, C. (2004). Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 64, 4768-4773. (Pubitemid 38930817)
22. Fisher, K.D., and Seymour, L.W. (2010). HPMA copolymers for masking and retargeting of therapeutic viruses. Adv. Drug Deliv. Rev. 62, 240-245.
23. Gainey, M.D., Manuse, M.J., and Parks, G.D. (2008). A hy-perfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon. J. Virol. 82, 9369-9380.
24. Ganesh, S., Gonzalez Edick, M., Idamakanti, N., et al. (2007). Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 67, 4399-4407. (Pubitemid 46815089)
25. Ganesh, S., Gonzalez-Edick, M., Gibbons, D., et al. (2008). In-tratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin. Cancer Res. 14, 3933-3941.
26. Ganesh, S., Gonzalez-Edick, M., Gibbons, D., et al. (2009). Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a pre-clinical model of head and neck cancer. Cancer Gene Ther. 16, 383-392.
27. Gros, A., Martinez-Quintanilla, J., Puig, C., et al. (2008). Biose-lection of a gain of function mutation that enhances adeno-virus 5 release and improves its antitumoral potency. Cancer Res. 68, 8928-8937.
28. Gros, A., Puig, C., Guedan, S., et al. (2010). Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Mol. Ther. 18, 903-911.
29. Guedan, S., Rojas, J.J., Gros, A., et al. (2010). Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol. Ther. 18, 1275-1283.
30. Hadjipanayis, C.G., Fellows-Mayle, W., and Deluca, N.A. (2008). Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. Mol. Ther. 16, 1783-1788.
31. 3 and leads to tumor regression. Cancer Res. 65, 5292-5300. (Pubitemid 40827341)
32. Harari, O.A., Wickham, T.J., Stocker, C.J., et al. (1999). Targeting an adenoviral gene vector to cytokine-activated vascular en-dothelium via E-selectin. Gene Ther. 6, 801-807. (Pubitemid 29243653)
33. Hautmann, S.H., Lokeshwar, V.B., Schroeder, G.L., et al. (2001). Elevated tissue expression of hyaluronic acid and hyaluroni-dase validates the HA-HAase urine test for bladder cancer. J. Urol. 165, 2068-2074.
34. Havenga, M.J., Lemckert, A.A., Grimbergen, J.M., et al. (2001). Improved adenovirus vectors for infection of cardiovascular tissues. J. Virol. 75, 3335-3342. (Pubitemid 32225896)
35. Israyelyan, A.H., Melancon, J.M., Lomax, L.G., et al. (2007). Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells. Hum. Gene Ther. 18, 457-473. (Pubitemid 46850137)
36. Iyer, A.K., Khaled, G., Fang, J., and Maeda, H. (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11, 812-818. (Pubitemid 44280021)
37. Jing, Y., Tong, C, Zhang, J., et al. (2009). Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res. 69, 1459-1468.
38. Kim, J., Cho, J.Y., Kim, J.H., et al. (2002). Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther. 9, 725-736. (Pubitemid 34971303)
39. Kim, J.H., Lee, Y.S., Kim, H., et al. (2006). Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J. Natl. Cancer Inst. 98, 1482-1493. (Pubitemid 44605593)
40. Kottke, T., Galivo, F., Wongthida, P., et al. (2008). Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol. Ther. 16, 1217-1226. (Pubitemid 351866052)
41. Kottke, T., Thompson, J., Diaz, R.M., et al. (2009). Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin. Cancer Res. 15, 561-569.
42. Kovar, J.L., Johnson, M.A., Volcheck, W.M., et al. (2006). Hya-luronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am. J. Pathol. 169, 1415-1426. (Pubitemid 351194374)
43. Kuriyama, N, Kuriyama, H., Julin, CM., et al. (2000). Pretreat-ment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum. Gene Ther. 11, 2219-2230.
44. Liu, D., Pearlman, E., Diaconu, E., et al. (1996). Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc. Natl. Acad. Sci. U.S.A. 93, 7832-7837. (Pubitemid 26277124)
45. Liu, T.C., Galanis, E., and Kirn, D. (2007). Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4, 101-117. (Pubitemid 46189539)
46. Lokeshwar, V.B., Rubinowicz, D., Schroeder, G.L., et al. (2001). Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J. Biol. Chem. 276, 11922-11932.
47. Maillard, L., Ziol, M., Tahlil, O., et al. (1998). Pre-treatment with elastase improves the efficiency of percutaneous adenovirus-mediated gene transfer to the arterial media. Gene Ther. 5, 1023-1030. (Pubitemid 28401303)
48. Mailliard, R.B., Wankowicz-Kalinska, A., Cai, Q., et al. (2004). a-Type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64, 5934-5937. (Pubitemid 39129387)
49. McCawley, L.J., Crawford, H.C., King, L.E., Jr., et al. (2004). A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res. 64, 6965-6972. (Pubitemid 39331006)
50. McKee, T.D., Grandi, P., Mok, W., et al. (2006). Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66, 2509-2513.
51. Mi, J., Li, Z.Y., Ni, S., et al. (2001). Induced apoptosis supports spread of adenovirus vectors in tumors. Hum. Gene Ther. 12, 1343-1352. (Pubitemid 32681848)
52. Miller, W.H., Brosnan, M.J., Graham, D., et al. (2005). Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats. Mol. Ther. 12, 321-327. (Pubitemid 41025103)
53. Mok, W., Boucher, Y., and Jain, R.K. (2007). Matrix metallo-proteinases-1 and-8 improve the distribution and efficacy of an oncolytic virus. Cancer Res. 67, 10664-10668. (Pubitemid 350145891)
54. Mok, W., Stylianopoulos, T., Boucher, Y., and Jain, R.K. (2009). Mathematical modeling of herpes simplex virus distribution in solid tumors: Implications for cancer gene therapy. Clin. Cancer Res. 15, 2352-2360.
55. Montel, V., Kleeman, J., Agarwal, D., et al. (2004). Altered met-astatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res. 64, 1687-1694. (Pubitemid 38428690)
56. Morrison, P.F., Laske, D.W., Bobo, H., et al. (1994). High-flow microinfusion: Tissue penetration and pharmacodynamics. Am. J. Physiol. 266, R292-R305. (Pubitemid 24056038)
57. Nagano, S., Perentes, J.Y., Jain, R.K., and Boucher, Y. (2008). Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res. 68, 3795-3802.
58. Netti, P.A., Berk, D.A., Swartz, M.A., et al. (2000). Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60, 2497-2503. (Pubitemid 30262444)
59. Parato, K.A., Senger, D., Forsyth, P.A., and Bell, J.C. (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 5965-5976.
60. Raki, M., Molberg, O., Tollefsen, S., et al. (2005). The effects of atorvastatin on gluten-induced intestinal T cell responses in coeliac disease. Clin. Exp. Immunol. 142, 333-340. (Pubitemid 41565250)
61. Rampling, R., Cruickshank, G., Papanastassiou, V., et al. (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 859-866. (Pubitemid 30303583)
62. Reynolds, P.N., Zinn, K.R., Gavrilyuk, V.D., et al. (2000). A tar-getable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol. Ther. 2, 562-578.
63. Ricci-Vitiani, L., Pallini, R., Biffoni, M., et al. (2011). Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824-828.
64. Richardson, R.M., Kells, A.P., Rosenbluth, K.H., et al. (2011). Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol. Ther. (in press).
65. Rosenbluth, K.H., Luz, M., Mohr, E., et al. (2011). Design of an in-dwelling cannula for convection-enhanced delivery. J. Neurosci. Methods 196, 118-123.
66. 2\+ in the replication and pathogenesis of rotavirus and other viral infections. Cell Calcium 28, 137-149.
67. Ryan, D.A., Mastrangelo, M.A., et al. (2010). A b-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol. Ther. 18, 1471-1481.
68. Sauthoff, H., Heitner, S., Rom, W.N., and Hay, J.G. (2000). Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum. Gene Ther. 11, 379-388. (Pubitemid 30101948)
69. Seymour, L.W., Cawood, R., and Fisher, K.D. (2008). Cellular carriers or free viruses? Curr. Opin. Mol. Ther. 10, 321-322.
70. Shinozaki, K., Suominen, E., Carrick, F., et al. (2006). Efficient infection of tumor endothelial cells by a capsid-modified ad-enovirus. Gene Ther. 13, 52-59. (Pubitemid 41823851)
71. Shuster, S., Frost, G.I., Csoka, A.B., et al. (2002). Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int. J. Cancer 102, 192-197. (Pubitemid 35168035)
72. Simpson, M.A. (2006). Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice. Am. J. Pathol. 169, 247-257.
73. Tseng, J.C., Granot, T., Digiacomo, V., et al. (2010). Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor. Cancer Gene Ther. 17, 244-255.
74. Uno, F., Fujiwara, T., Takata, Y., et al. (2001). Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. Cancer Res. 61, 7855-7860. (Pubitemid 33049375)
75. Victor, R., Chauzy, C., Girard, N., et al. (1999). Human breast-cancer metastasis formation in a nude-mouse model: Studies of hyaluronidase, hyaluronan and hyaluronan-binding sites in metastatic cells. Int. J. Cancer 82, 77-83. (Pubitemid 29266110)
76. Watanabe, Y., Kojima, T., Kagawa, S., et al. (2010). A novel translational approach for human malignant pleural meso-thelioma: Heparanase-assisted dual virotherapy. Oncogene 29, 1145-1154.
77. White, E., Bienemann, A., Megraw, L., et al. (2011a). Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery. Cancer Gene Ther. 18, 358-369.
78. White, E., Bienemann, A., Sena-Esteves, M., et al. (2011b). Evaluation and optimization of the administration of recombinant adeno-associated viral vectors (serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by convection-enhanced delivery to the striatum. Hum. Gene Ther. 22, 237-251.
79. Willmon, C., Harrington, K., Kottke, T., et al. (2009). Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol. Ther. 17, 1667-1676.
80. Yamamoto, M., and Curiel, D.T. (2010). Current issues and future directions of oncolytic adenoviruses. Mol. Ther. 18, 243-250.
81. Yoon, A.R., Kim, J.H., Lee, Y.S., et al. (2006). Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Hum. Gene Ther. 17, 379-390.
82. Yun, C.O. (2008). Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr. Opin. Mol. Ther. 10, 356-361.